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Abstract
The screening for chronic kidney disease (CKD) patients needs the measurement of serum markers like creatinine. Our previous
results indicated that urinary excretion of b-trace protein (BTP), a low-molecular-weight protein (23–29kDa), is increased in CKD
patients from stage 2. The aim of this study was to assess the major determinants of urinary excretion of BTP and to evaluate its
feasibility as noninvasive marker of glomerular filtration rate (GFR) impairment.
We studied 355CKD patients (198males), aged 15 to 83 years, in stable clinical conditions, classified in the different stages of CKD
on the basis of GFR (renal clearance of 99mTc-diethylenetriamine penta-acetic acid). At the same time, we measured serum and
urinary creatinine and BTP, and urinary albumin. Urinary excretion of BTP and albumin was expressed as mg/g urinary creatinine.
Fractional clearance of BTP was calculated as the ratio of BTP clearance to creatinine clearance (%).
Urinary excretion of BTP is mainly determined by its serum concentration and by the level of GFR, and to a lower extent by urinary
albumin excretion. In fact, urinary BTP (U-BTP) and fractional clearance of BTP progressively and significantly increased along with
the reduction of GFR and the concurrent rise in serum BTP (S-BTP). The relationship of U-BTP with GFR was very similar to that of
S-BTP with GFR: U-BTP mirrors S-BTP. The accuracy of U-BTP to screen patients with GFR <90mL/min/1.73m2 was good (area
under the curve 0.833), its sensitivity was 76.9%, specificity 80%, and positive predictive value 84.9%. Sensitivity of U-BTP was quite
similar to that of S-BTP and serum creatinine.
Themajor determinants of urinary excretion of BTP are S-BTP andGFR. U-BTPmay be a suitable noninvasivemarker to screen the
general population for detection of GFR <90mL/min/1.73m2.
Abbreviations: AKI = acute kidney injury, AUC = area under the curve, B2M = b2-microglobulin, BTP = b-trace protein, CKD =
chronic kidney disease, DTPA = diethylenetriamine penta-acetic acid, GFR = glomerular filtration rate, LMWP = low-molecular-
weight protein, MW =molecular weight, NPV = negative predictive value, PPV = positive predictive value, ROC = receiver-operating
characteristic, S-BTP = serum b-trace protein, S-Cr = serum creatinine, U-Alb = urinary albumin, U-BTP = urinary b-trace protein.
Keywords: b-trace protein, chronic kidney disease, glomerular filtration rate, low-molecular-weight proteins, noninvasive
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1progression of CKD and possibly reduce the number of incident
patients who need the replacement of renal function. Further-
more, a beneficial effect on cardiovascular system is expected,
since the cardiovascular risk increases with the impairment of
glomerular filtration rate (GFR). Finally, the measurement, or the
estimate, of GFR is essential to establish the stage of CKD and to
reduce the burden of drug nephrotoxicity, even in patients
without evidence of CKD. Urinalysis and urinary albumin (U-
Alb) excretion, which are useful markers of kidney disease,
cannot quantify the impairment of GFR. Therefore, the screening
for subjects with impaired GFR needs the measurement of serum
markers like serum creatinine (S-Cr) and/or cystatin C, or the
measurement of creatinine clearance. Low-molecular-weight
proteins (LMWPs) are cleared from the blood mainly through
glomerular filtration, followed by an almost complete reabsorp-
tion by proximal tubular cells.[1,2] After degradation to smaller
peptides and amino acids, their fragments are reabsorbed into
peritubular circulation, whereas urinary excretion of LMWPs is
null. Due to this peculiar renal handling, the serum concentration
of cystatin C, b2-microglobulin (B2M), and other LMWPs has
been proposed as a serum marker of GFR impairment, whereas
the increase in their urinary excretion is considered a marker of
tubular damage. Indeed, an increased urinary excretion of
LMWPs can be observed also in patients with very low GFR, at
end-stage renal disease.[3,4] b-trace protein (BTP), which is also
known as lipocalin-type prostaglandin D synthase, is a small
Table 1
Demographic and clinical characteristics of the 355 examined
patients (males 198, females 157), and underlying kidney disease.
Range Median IQR 25–75
Age, y 15–83 53 41.3–64.0
Weight, kg 36.6–131 71 60.7–82.5
Height, cm 140–195 164 157.0–171.8
Body surface area, m2 1.25–2.53 1.76 1.62–1.93
Body mass index, kg/m2 16.3–40.0 26.1 23.2–29.4
Serum creatinine, mg/dL 0.4–12.1 1.35 0.9–2.6
Kidney disease
Glomerulonephritis 91 (25.6)
Chronic renal failure 65 (18.3)
Ischemic nephropathy 50 (14.1)
Interstitial nephropathy 42 (11.8)
Diabetic nephropathy 30 (8.5)
Polycystic and other cystic
kidney disease
25 (7.0)
Renal transplant recipients 19 (5.4)
Donadio and Bozzoli Medicine (2016) 95:49 Medicineprotein (23–29kDa, depending on the different glycosylation of
the molecule) isolated primarily from cerebrospinal fluid.[5–7]
Like other LMWPs, BTP is taken up by tubular cells and actively
degraded within their lysosomes to produce the N-terminal-
truncated form.[8] Previous studies demonstrated that serum BTP
(S-BTP) is an adequate marker of GFR impairment with a
diagnostic accuracy similar to those of S-Cr, cystatin C, and
B2M.[9–12] Our previous data indicate that urinary excretion of
cystatin C, B2M, and retinol-binding protein is increased when
GFR is below 30mL/min/1.73m2, whereas an increase in urinary
BTP (U-BTP) is observed already in patients at CKD stage 2.[13]
These results suggest the feasibility of LMWPs and namely BTP
as a urinary marker to screen for patients with GFR impairment.
The aim of this study, performed in a group of CKD patients
with different levels of GFR, was to assess the major determinants
of urinary excretion of BTP and to evaluate its feasibility as a
noninvasive marker of GFR impairment.Kidney donors 9 (2.5)
Others 24 (6.8)
Data are expressed as number (percent), range, median, and interquartile range (IQR) 25–75.2. Patients and methods
2.1. Patients
Setting was the laboratory for the evaluation of GFR of the
division of nephrology at the Department of Clinical and
Experimental Medicine of the University of Pisa.
Inclusion criteria were as follows: measurement of GFR for the
assessment of renal function in CKD patients clinically stable; in
renal transplant recipients; in potential living kidney donors, and in
patientswith cancer scheduled for chemotherapy. Exclusion criteria
wereas follows:recentadministration(within2weeks)ofpotentially
nephrotoxic drugs or contrast media; acute kidney injury (AKI).
Four hundred eighty-five patients were examined (Fig. 1). The
great majority of examined patients were on ambulatory follow-
up of already diagnosed kidney diseases. Ninety patients did not
fulfill the inclusion criteria. The measurement of the index test (U-
BTP, mg/g creatinine) was obtained in 386 patients. The
measurement of GFR (reference test) was not adequate in 34
patients, mainly due to technical reasons (inability of some
patients to urinate on command, or inadequate volume of bloodFigure 1. Flow of participants during the study.
2sampling). The remaining 355 CKD patients affected by different
kidney diseases, in stable clinical conditions, with various degree
of impairment of renal function, are analyzed in the present study
(Table 1, Suppl File Urinary BTP Medicine.xls, http://links.lww.
com/MD/B441). The ethnicity was Caucasian for all patients.
The study was approved by the Institutional Ethical Commit-
tee of Azienda Ospedaliero-Universitaria Pisana and was
conducted in accordance with guidelines ofHelsinki declarations.
All patients gave their informed consent.2.2. Methods
Glomerular filtration rate was measured, in the morning before
breakfast, with a radio-isotopic method, as the renal clearance of
99mTc-diethylenetriamine penta-acetic acid (DTPA).[14,15]. The
measurement of 99mTc-DTPA clearance is a reference method for
the measurement of GFR. In fact, its renal clearance is only slightly
lower than inulinclearance,due toamodest linktoplasmaalbumin.
Thecoefficientofvariationof99mTc-DTPAGFR,testedonduplicate
measurement, was approximately 8% (our laboratory data). The
resultswere adjusted, as usual, to the standardbody surface of 1.73
m2.PatientswereclassifiedinthedifferentstagesofCKDonthebasis
of the value of the GFR measurement, using the modified
classification of CKD, which divides the stage 3 into 3a (GFR
45–60mL/min/1.73m2) and 3b (GFR 30–45mL/min/1.73m2).[16]
Blood and urine samples were drawn at the time of GFR
measurement. Serum and urine samples were divided into
Eppendorf tubes, which were hermetically closed and stored at
20°C, up to the time of biochemical determinations.
Serum and urinary concentrations of creatinine were measured
with a rate-blanked creatinine/Jaffémethod (CREARoche/Hitachi
automated analysis for Hitachi 917, Roche Diagnostics, Man-
nheim, Germany; reference intervals for serum concentration are
0.50–0.90mg/dL in women and 0.70–1.20mg/dL in men).
Serum and urinary concentrations of BTP were measured with a
particle-enhanced immune-nephelometric method (N Latex BTP
assay, Siemens Healthcare GmbH, Erlanger, Germany). Upper
referencerange(95percentile),menandwomen:serum=0.70mg/L,
urine=3.75mg/L; coefficient of variation within laboratory
<6.6%.[17]
Figure 2. Correlation with glomerular filtration rate (GFR) of serum creatinine, serum, and urinary b-trace protein (BTP). The data of individual patients and the
regression lines are plotted. The regression equations and the coefficients of correlation with GFR are reported.
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BTP (2.5%–97.5%) are 0.37 to 0.77mg/L in men and 0.40 to
0.70mg/L in women[12]; upper reference limits (97.5 percentile)
for U-BTP were 7.79mg/L for men and 3.13mg/L for women[18];
upper reference limits (90 percentile) for U-BTP were 3.5mg/g
creatinine for men and 2.5mg/g creatinine for women.[19]
Urinary albumin was measured with an immune-nephelomet-
ric method (N antiserum to human albumin, Siemens).
Fractional clearance of BTP was calculated as: 100 (U-BTP
[mg/L]S-Cr [mg/dL])/(S-BTPurinary creatinine).
The renal threshold for tubular reabsorption of BTP was
estimated from the plot of the logarithm of U-BTP (mg/L) versus
S-BTP (mg/L).[20]2.3. Statistical analysis
The correlation coefficients between GFR and the serum and
urinary markers were measured. The significance of the differ-
ences among correlation coefficients was tested.[21] The signifi-
cance of the differences between 2 independent samples and
between 2 paired samples was tested using the nonparametric
Mann–Whitney and Wilcoxon tests, respectively. The diagnostic
accuracy of markers was assessed using receiver-operating
characteristic (ROC) analysis. On the basis of the value of the
area under the curve (AUC), the accuracy was considered
excellent (AUC=0.90–0.99), good (AUC=0.80–0.89), fair
(AUC=0.70–0.79), and poor (AUC=0.60–0.69). Stepwise
multiple regression analysis was used to establish the determi-
nants of U-BTP excretion.[22]
Statistical analysis was performed using MedCalc (version
16.2.0; MedCalc Software, Mariakerke, Belgium). P<0.05 was
considered significant.3. Results
Urinary excretion of BTP (U-BTP), which was modest in patients
with GFR >90mL/min/1.73m2, progressively increased in
patients with lower GFR. The statistically significant negative
correlation found between U-BTP and the value of GFR (r=
0.650, P<0.000001) is shown in Fig. 2, where are represented,
for comparison, also the correlations of S-Cr and S-BTP with
GFR in the same patients. S-Cr, serum concentrations, and
urinary excretion of BTP were significantly higher in men than in
women (P<0.0001), and the values of GFR were significantly
lower in men (P<0.05) (Table 2). No significant difference was
found for age and U-Alb excretion according to the sex of3patients. The values of U-BTP in patients at CKD stage 2
(GFR 60–90mL/min/1.73m2) were already significantly higher
(P<0.05) than in patients at CKD stage 1 (GFR >90mL/min/
1.73m2) (Table 3). The difference versus patients at CKD stage 1
progressively increased and became highly significant in patients
with lower GFR (P<0.001 at stage 3a, P<0.0001 at stages 3b,
4, and 5). Fractional clearance of BTP also progressively and
significantly increased in patients with reduced GFR, indicating
that tubular reabsorption of BTP decreases according to the stage
of CKD (Table 3). U-Alb excretion resulted significantly higher
(P<0.05) only in patients with GFR<45mL/min/1.73m2 versus
those with GFR>90 (Table 3). The negative correlation between
U-BTP and GFR became even more significant when patients
were clustered in groups according to their CKD stage. The
exponential terms of the increase of U-BTP and of fractional
clearance of BTP with the reduction of GFR were similar to
that of S-BTP with GFR (Fig. 3). The renal threshold for
tubular reabsorption of BTP is reached for a value of
approximately 1mg/L of S-BTP (Fig. 4).
Multiple regression analysis (stepwise) indicated that the
determinants of U-BTP are mainly S-BTP and GFR values,
and to a lower extent U-Alb excretion. Stepwise analysis excluded
the other tested parameters (age, body weight, and height)
from the model (Table 4). The regression equation was: U-BTP
(mg/g creatinine)=6.4+ (2.46S-BTP [mg/L]) (0.0698GFR
[mL/min/1.73m2])+ (0.0082U-Alb [mg/g] creatinine); R2
adjusted=0.52.
The accuracy of U-BTP to screen patients with GFR lower than
90mL/min/1.73m2was quite satisfactory. In fact, using as cut-off
value of U-BTP >2.24mg/g creatinine, the accuracy was good
(AUC 0.833, 95% confidence interval [CI] 0.790–0.870, P<
0.00001), the sensitivity was 76.9%, and the specificity 80.0%
(Table 5).[22]
The accuracy of S-Cr (AUC=0.928, 95% CI 0.896–0.953,
P<0.00001) and S-BTP (AUC=0.909, 95% CI 0.873–0.937,
P<0.00001) resulted excellent, and significantly better than that
of U-BTP (P<0.01 vs S-Cr, P<0.05 vs S-BTP). Anyway, the
sensitivity of U-BTP was identical to those of S-Cr and S-BTP.
Assuming the prevalence of 58.3%of subjects with GFR<90mL/
min/1.73m2, found in epidemiological analysis of general
population,[23] the positive predictive value (PPV) becomes
84.9%, indicating this probability that a patient with a positive
test (U-BTP >2.24) has a GFR <90mL/min/1.73m2. As
expected, a screening based on blood test has better PPV
(97.1% for both S-Cr and S-BTP), whereas the negative
predictive values (NPVs) were quite similar to that of U-BTP.
2 [23]
Table 2
Serumcreatinine concentrations, serum concentrations, and urinary excretion ofb-trace protein, urinary albumin excretion, and values of
glomerular filtration rate.
n Range Median IQR 25–75
All patients
Age, y 355 15–83 53 41.3–64.0
Serum creatinine, mg/dL 355 0.4–12.1 1.35 0.9–2.6
Serum b-trace protein, mg/L 347 0.3–12.1 1.35 0.9–2.8
Urinary b-trace protein, mg/g creatinine 355 0.07–54.5 5.69 1.9–12.7
Urinary albumin, mg/g creatinine 353 0–1950 12.4 3.4–93.3
Glomerular filtration rate, mL/min/1.73m2 355 3.6–134.9 46.85 23.3–70.6
Men
Age, y 198 15–79 51.74 42–64
Serum creatinine, mg/dL 198 0.60–12.13 1.73
∗∗
1.10–3.22
Serum b-trace protein, mg/L 194 0.36–12.06 1.68
∗∗
1.03–3.11
Urinary b-trace protein, mg/g creatinine 198 0.07–54.53 7.46
∗∗
2.82–15.52
Urinary albumin, mg/g creatinine 197 0–1950.0 11.8 2.7–91.7
Glomerular filtration rate, mL/min/1.73m2 198 3.6–127.4 41.5 ° 21.1–65.8
Women
Age, y 157 17–83 54.0 40.8–65
Serum creatinine, mg/dL 157 0.40–7.02 0.97 0.75–1.67
Serum b-trace protein, mg/L 153 0.27–11.15 1.01 0.74–2.30
Urinary b-trace protein, mg/g creatinine 157 0.12–48.21 3.64 1.44–8.36
Urinary albumin, mg/g creatinine 156 0–1769.2 12.8 5.0–96.9
Glomerular filtration rate, mL/min/1.73m2 157 4.6–134.9 53.2 29.6–75.2
The results obtained in all patients and separately in men and women are reported. Data are expressed as number, range, median, and interquartile range (IQR) 25 to 75. The significance of the differences
between men and women are reported (
∗∗
P<0.0001;
∗∗∗
P<0.05).
Table 3
Serum creatinine concentrations, serum concentrations, urinary excretion, and fractional clearance of b-trace protein, urinary excretion
of albumin, and values of glomerular filtration rate.
GFR >90mL/
min/1.73m2
GFR >60 to <90mL/
min/1.73m2
GFR >45 to
<60mL/min/1.73m2
GFR >30 to
<45mL/min/1.73m2
GFR >15 to
<30mL/min/1.73m2
GFR <15mL/
min/1.73m2
Number of patients 30 103 49 55 60 58
Age, y 35.4±12.4 48.7±15.1
∗∗
56.9±13.2
∗∗
54.6±15.2
∗∗
56.9±12.7
∗∗
56.9±13.5
∗∗
Serum creatinine, mg/dL 0.70±0.15 0.96±0.27
∗∗
1.10±0.25
∗∗
1.67±0.41
∗∗
2.67±0.89
∗∗
5.48±2.00
∗∗
Serum b-trace protein, mg/L 0.66±0.20 0.91±0.30
∗∗
1.10±0.45
∗∗
1.82±0.60
∗∗
2.66±0.69
∗∗
5.61±2.01
∗∗
Urinary b-trace protein,
mg/g creatinine
1.86±1.89 4.14±4.73
∗∗∗
4.94±4.33
∗
7.60±5.52
∗∗
14.35±8.89
∗∗
20.24±11.79
∗∗
Fractional clearance of
b-trace protein,%
2.03±1.99 4.52±5.67
∗∗∗
5.24±4.90
∗
7.65±6.55
∗∗
14.73±9.73
∗∗
19.82±10.56
∗∗
Urinary albumin, mg/g creatinine 40.2±61.9 70.4±226.2 71.0±136.5 82.5±183.6
∗∗∗
112.4±160.0
∗∗∗
164.4±287.6
∗∗∗
GFR, mL/min/1.73m2 107.7±11.9 72.6±8.2
∗∗
53.2±4.3
∗∗
37.8±4.4
∗∗
23.0±4.6
∗∗
9.5±3.1
∗∗
Patients are clustered according to the stages of chronic kidney disease. Data are expressed as number, mean± standard deviations. The significance of the differences versus the patients with GFR >90mL/
min/1.73m2 are indicated:
∗
P<0.001;
∗∗
P<0.0001;
∗∗∗
P<0.05.
Donadio and Bozzoli Medicine (2016) 95:49 MedicineThe values of AUC, sensitivity, and specificity of the 3 index
tests as indicators of GFR <60mL/min/1.73m2 were similar to
those found as indicators of GFR <90mL/min/1.73m2, whereas
the cut-off values were higher. Due to the lower prevalenceFigure 3. Correlation with glomerular filtration rate (GFR) of serum concentration, u
clustered according to chronic kidney disease (CKD) stage. Mean values and sta
4(8.1%) of patients with GFR <60mL/min/1.73m , the PPVs
were quite low, whereas the NPVs were definitely high. Similar
results of sensitivity, specificity, PPV, and NPV of U-BTP were
found versus GFR predicted using modification of diet in renalrinary excretion, and fractional clearance of b-trace protein (BTP). Patients are
ndard errors of the mean are represented for BTP and for GFR.
Figure 4. b-trace protein (BTP): urinary versus serum concentrations
(semilogarithmic scale).
Donadio and Bozzoli Medicine (2016) 95:49 www.md-journal.comdisease (4 variables, isotope dilution mass spectrometry), CKD-
EPI Cr, and CKD-EPI Cr-Cys formulae (Suppl Table, http://links.
lww.com/MD/B442).
The sensitivity of the examined test, to screen the patients with
GFR <90mL/min/1.73m2, increases to ∼90% using lower cut-
off values: U-BTP 1.08mg/g creatinine, S-BTP=0.71mg/L; S-
Cr=0.8mg/dL. In the mean time, the specificity and PPVs of the
tests decrease, whereas NPVs increases.
The accuracy of U-BTP, to screen for a GFR<90mL/min/1.73
m2, was higher in men than in women (AUC 0.866 and 0.783,
respectively) (Fig. 5). Also, the cut-off value was different in menTable 4
Multiple linear regression modeling (stepwise) for urinary b-trace pr
concentration (mg/L), sex, GFR (mL/min/1.73m2), urinary albumin exc
index.
Independent variables Coefficient
Constant 6.33
Serum b-trace protein, mg/L 2.39
Sex, male 2.06
Glomerular filtration rate, mL/min/1.73m2 0.0682
Urinary albumin, mg/g creatinine 0.0085
Variables not included in the model: age, body weight, height, and body mass index.
GFR=glomerular filtration rate.
Table 5
Receiver-operating curve (ROC) analysis of serum creatinine and seru
rate (GFR) lower than 90 or 60mL/min/1.73m2.
Cut-off AUC AUC, 95% con
GFR <90mL/min/1.73m2, prevalence 59.3%
Serum creatinine, mg/dL >0.94 0.928
∗
0.896
Serum b-trace protein, mg/L >0.89 0.909
∗
0.873
Urinary b-trace protein, mg/g creatinine >2.24 0.833
∗
0.790
GFR <60mL/min/1.73m2, prevalence 8.1%
Serum creatinine, mg/dL >1.25 0.928
∗
0.896
Serum b-trace protein, mg/L >1.42 0.918
∗
0.885
Urinary b-trace protein, mg/g creatinine >4.38 0.816
∗
0.771
The cut-off values, the area under the curve (AUC), and the values of sensitivity and specificity of the tests ar
positive predictive values (PPVs), the negative predictive values (NPVs), and the likelihood ratios of the
5(U-BTP >4.32mg/g creatinine) than in women (2. 24mg/g
creatinine).
4. Discussion
It is generally acknowledged that a more significant reduction in
the progression of CKD patients to advanced renal failure is
linked to an earlier detection of CKD, possibly when the
impairment in GFR is still moderate. Furthermore, the
identification of patients with impaired renal function is relevant
to reduce the risk of cardiovascular disease, to decrease the
burden of nephrotoxicity due to the administration of inadequate
doses of drugs or xenobiotics, and to reduce the risk of
postsurgical AKI. Note that a reduction in GFR is frequent in
aged patients, independently from the presence of CKD, and S-Cr
underestimates the impairment of GFR in aged patients with
reduced muscle mass.
A screening for early impairment of GFR responds to both
classic and revisited Wilson and Jungner screening criteria.[24,25]
Many factors affect the possibility of an efficient screening for
functional renal impairment. First, the performance of the
diagnostic test, that is its sensitivity and specificity, which, together
with the prevalence of the disease in the examined population,
determine the PPVandNPVof the test. In the screening procedure,
it is important to avoid either high percentages of false-positive
results, whichmay lead to negative psychological consequences for
patients, or of false-negative results. Also relevant, for the practical
execution, is the simplicity of the administered test. Thus, a
screening based on a urinary marker has an evident advantage,
being noninvasive, in comparison with a screening based on a
blood marker. In fact, using a free self-test for screening
albuminuria in the general population resulted in a large response
and a number of newly detected diseases.[26]otein excretion (mg/g creatinine) based on serum b-trace protein
retion (mg/g creatinine), age, body weight, height, and body mass
Standard error t Probability
0.273 8.773 <0.0001
0.717 2.878 <0.005
0.0174 3.915 0.0001
0.00175 4.859 <0.0001
mand urinaryb-trace protein as indicators of a glomerular filtration
fidence interval Sensitivity, % Specificity, % PPV, % NPV, %
–0.953 76.9 96.7 97.1 74.2
–0.937 77.0 96.7 97.1 74.2
–0.870 76.9 80.0 84.9 70.4
–0.952 79.73 93.23 50.9 98.1
–0.945 75.12 96.92 68.3 97.8
–0.865 77.03 77.44 23.1 97.5
e reported. On the basis of the prevalence in the general population of the GFR values, we calculated the
different tests. The statistical significance of the AUC values is indicated:
∗
P<0.00001.
Figure 5. Receiver-operating curve (ROC) analysis in men (A) and in women (B) of serum creatinine and serum and urinary b-trace protein (BTP) as indicators of a
glomerular filtration rate (GFR) lower than 90mL/min/1.73m2. The values of cut-off and the areas under the curve (AUCs) are reported.
Donadio and Bozzoli Medicine (2016) 95:49 MedicineUp to now, urinary biomarkers have been proposed for the
early diagnosis and prognosis of AKI,[27] to predict cardiovascu-
lar risk or progression of CKD,[28] or to evaluate tubular damage
and nephrotoxicity.[29,30] No urinary biomarker has been
validated up to now for the early diagnosis of GFR impairment
in CKD patients. Our previous data indicated that U-BTP
increased in CKD patients with GFR <90mL/min/1.73m2.[13]
The present study, for the first time, aimed to evaluate the
determinants of U-BTP, the relationship between U-BTP and
measured GFR, and the feasibility of BTP as a urinary biomarker
to screen early GFR impairment. The study was performed in a
group of clinically stable patients with different degrees of
impairment in GFR (from normality to advanced renal failure).
We excluded patients with inherited tubular disease or acquired
tubular malfunction, since high values of U-BTP may be found in
these patients. The weakness of this study is the lack of an
external control group. One limitation with measuring BTP, as
unlike other novel biomarkers like cystatin C, is the lack of
reference standard. Hence, there may be significant inter and
intralaboratory variation. The strength of the study is the number
of examined patients and the direct measurement of GFR with a
“gold standard” method.
Our results indicate that, differently from other LMWPs, BTP
is present in the urine of patients with normal GFR, and its
urinary excretion progressively increases along with the reduc-
tion of GFR and the concurrent rise in S-BTP. In the mean time,
the fractional clearance of BTP progressively increases with
the reduction of GFR, suggesting a decrease in its tubular
reabsorption. In fact, urinary excretion of BTP, as demonstrated
in multiple regression analysis, is determined by its serum
concentration, by albumin excretion, and, inversely, by GFR. A
positive correlation between U-BTP and U-Alb had been already
found in diabetic patients[19] and also in renal patients.[31] The
interpretation of this finding may be different: from increase in
glomerular permeability to competition at tubular level for the
same transport system.[32,33] BTP and albumin possibly compete
for the same receptor complex megalin/cubilin/amnionless.[34] A
competition with albumin has already been demonstrated for
other LMWPs.[33] After glomerular filtration, BTP also under-
goes proximal tubular reabsorption.[8] The system appears
already saturated for the transport of BTP at normal GFR, as
indicated by the measurable excretion of BTP in these patients.
On the contrary, the filtration coefficient of BTP (molecular6weight [MW] 23–29kDa) is probably lower than those of smaller
molecules like creatinine and B2M. This hypothesis is supported
by the fact that fractional clearance of BTP does not exceed 40%,
even in patients at CKD stage 5. In these patients, if glomerular
filtration of BTP was free, tubular reabsorption of BTP should be
null and its fractional clearance should approximate 100%. In
fact, fractional clearance of B2M (MW 11.8kDa, filtration
coefficient ∼1) reaches the value of 90% in patients with very low
GFR.[35]
The results of the present study are in large agreement with
other studies that evaluated the excretion of BTP in renal disease.
In fact, literature data indicate a higher urinary excretion of BTP
in hypertensive patients, increasingly along with advance in renal
dysfunction, in diabetic patients with subclinical renal injury or
with cardiovascular complications, in lupus nephritis patients
according to the activity of disease and efficacy of treatment, and
also in Anderson–Fabry disease.[36–43]
Other data strongly suggest that BTP may be useful as a
diagnostic marker for early detection of renal tubular dam-
age.[18,44] Urinary excretion of BTP was also correlated with
urinary excretion of other LMWPs, commonly used as markers
of tubular damage, but was also significantly correlated with the
impairment of estimated GFR.[31]
Different literature data indicate a difference in U-BTP, linked
to sex. In fact, U-BTP was higher in men than in women, either
in normal subjects or in CKD patients.[18,19] Similarly, the
best cut-off values of U-BTP to predict renal disease or diabetic
microalbuminuria resulted higher in men (3.2–4.2mg U-BTP/g
creatinine) than inwomen (2.9–2.8mg/g).[19] These cut-off values
are very similar to those that we found as the best values to screen
for GFR <90mL/min/1.73m2 in men (4.32mg/g creatinine) and
in women (2.24mg/g creatinine).
The novelty of the present paper is the finding that the
relationship between U-BTP and GFR is very similar to that
between S-BTP and GFR: U-BTP mirrors S-BTP. The possible
explanation of this behavior is that any increase in the glomerular
and then tubular charge of BTP escapes tubular reabsorption,
which is already saturated at normal GFR and is excreted into the
urine due to the low renal threshold for tubular reabsorption
of BTP.
Our results also indicate that U-BTP may be an adequate
indicator of GFR <90mL/min/1.73m2, with a sensitivity similar
to those of S-BTP and S-Cr. The PPV of U-BTPwas also similar to
[10] Priem F, Althaus H, Jung K, et al. Beta-Trace protein is not better than
Donadio and Bozzoli Medicine (2016) 95:49 www.md-journal.comthose of S-BTP and S-Cr, assuming that a GFR <90mL/min/
1.73m2 has a prevalence of 58.3%, as found in the general
population.[23] Note that the prevalence of subjects with eGFR
<90mL/min/1.73m2 was even higher (75.6%) in a community-
based screening for CKD among populations older than
40 years.[45] The higher incidence of the disease would increase
the PPV of the test, whereas a lower cut-off value would increase
sensitivity and decrease specificity and PPV. To the contrary,
a higher cut-off value (U-BTP >4.32mg/g creatinine) strongly
suggests a GFR <60mL/min/1.73m2. The development of a
simple “point-of-care” urine dip test based on urine BTP could
simplify the screening for renal diseases. In fact, the concurrent
determinations of U-BTP and U-Alb should meliorate the
accuracy of the screening and might single out the presence of
CKD and/or of GFR impairment. On the basis of our data, the
positivity of both U-Alb and U-BTP suggests the presence of
kidney disease, with an impairment in GFR. The negativity of
both tests indicates absence of kidney disease and no GFR
impairment. The positivity of U-Alb, whereas U-BTP is negative,
indicates the presence of kidney disease without impairment in
GFR. The negativity U-Alb associated with a positive U-BTP
should indicate an impairment in GFR without kidney disease.
These possibility needs to be confirmed by further studies.5. Conclusions
Urinary BTP seems to be an adequate biomarker to screen the
general population for a slight impairment in GFR (<90mL/min/
1.73m2). Further studies in general population and in high-risk
populations are warranted to prove this hypothesis.Acknowledgments
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